We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

5 hedge funds and large institutions have $517K invested in Biotech Acquisition Company Unit in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $443K → $517K (+$74K)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$112K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$42.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$397K – – –
CS
2
Clear Street
New York
$112K +$112K +11,284 +161,200%
Morgan Stanley
3
Morgan Stanley
New York
$5K -$42.5K -4,296 -89%
UBS Group
4
UBS Group
Switzerland
$2K – – –
TRCT
5
Tower Research Capital (TRC)
New York
$1K – – –

BIOTU Hedge Fund Activity: Q3 2022 in Review

5 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q3 2022, worth a combined $517K — up 17% from $443K a quarter earlier.

Fund positioning in BIOTU was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Clear Street, adding an estimated $112K. The largest seller was Morgan Stanley, cutting an estimated $42.5K.

  • 5 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $517K of Biotech Acquisition Company Unit stock for Q3 2022, up 17% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Unit positions in Q3 2022 and 0 closed out.
  • The largest Biotech Acquisition Company Unit buyer in Q3 2022 was Clear Street, an estimated $112K added.
  • The largest Biotech Acquisition Company Unit seller in Q3 2022 was Morgan Stanley, an estimated $42.5K sold.

Based on aggregated 13F filings for Q3 2022.